New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:05 EDTJAZZJazz Pharmaceuticals agrees to acquire rights to defibrotide in Americas
Jazz Pharmaceuticals announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals under which a subsidiary of Jazz Pharmaceuticals will acquire from Sigma-Tau rights to defibrotide in the United States and all other countries in the Americas. Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Gentium S.p.A., which was acquired by Jazz earlier this year. As part of the agreement, Sigma-Tau would receive an upfront payment of $75M upon closing of the transaction. Sigma-Tau would be eligible to receive milestone payments of $25M upon the acceptance for filing by the FDA of the first NDA for defibrotide for VOD and up to an additional $150M based on the timing of potential FDA approval of defibrotide for VOD. Jazz expects to fund the transaction with cash on hand and that the transaction will close during the third quarter of 2014, subject to customary closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
15:52 EDTJAZZUSPTO review of Jazz patents negative but not unexpected, says BMO Capital
Subscribe for More Information
15:46 EDTJAZZJazz Pharmaceuticals says USPTO moving forward with review of Xyrem patents
Subscribe for More Information
July 24, 2015
11:59 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry discusses the strengths and weaknesses of TEVA’s preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and the perspectives on recent updates in the Jazz Pharmaceuticals' Xyrem patent case on an Analyst/Industry conference call to be held on July 27 at 11 am.
July 20, 2015
10:26 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals / Generics Analyst Gerberry, along with MEDACorp Specialists Michael Belliveau, PhD and Shashank Upadhye, JD, discuss the strengths and weaknesses of TEVA's preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and perspectives on recent updates in the JAZZ Xyrem patent case on an Analyst/Industry conference call to be held on July 22 at 2 pm.
July 17, 2015
08:38 EDTJAZZLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use